PTC Therapeutics, Inc.
PTCTPTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare genetic disorders and other serious conditions. Founded in 1998, the company utilizes innovative drug discovery platforms to develop gene-specific and small molecule treatments aimed at improving patient outcomes. PTC’s portfolio includes therapies for neuromuscular, neurological, and rare genetic diseases.
Company News
Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slight...
Royalty Pharma has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in sales-based milestones. Following the transaction, Royalty Pharma will own 100% of the tiered 8% to 16% royalty on worldwide net sales of Evrysdi, an FDA-approved spinal muscular atrophy treatm...
PTC Therapeutics' CEO Matthew Klein highlighted the commercial potential of Sephience, a drug for treating phenylketonuria (PKU), projecting significant market opportunities in the U.S. and internationally. The company expects to reach cash flow breakeven with growing sales and believes most patients will respond positively to the treatment.
Novartis reported strong Q2 2025 financial performance with 11% sales growth, double-digit core operating income increase, and raised full-year guidance. Key growth drivers included oncology and specialty medicine brands like Kisqali, Entresto, and Pluvicto.
Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (CAPR) after the company announced that the FDA will hold an advisory committee meeting for its Biologics License Application, causing the stock price to drop.
